Alida Bio Unlocks RNA's Hidden Language with New Tri-Mod Technology

SAN DIEGO, CA – April 15, 2026 – In a move that could significantly advance our understanding of cellular function and disease, Alida Biosciences today launched a new service capable of reading a hidden layer of biological information written on our RNA. The San Diego-based company's EpiPlex™ Tri-Mod™ Service is the first commercial solution to simultaneously detect and quantify three critical mRNA modifications—N6-methyladenosine (m6A), inosine, and pseudouridine—along with gene expression levels, all within a single, streamlined workflow.

This development provides researchers with a powerful tool to explore the epitranscriptome, a complex and dynamic system of chemical marks on RNA that governs how genetic instructions are executed. While genomics tells us the blueprint of life, and transcriptomics reveals which genes are switched on, epitranscriptomics deciphers the subtle, real-time edits that control a gene's ultimate fate, offering a more nuanced view of health and disease.

Cracking the Epitranscriptomic Code

The central dogma of molecular biology—DNA makes RNA, and RNA makes protein—has long been the foundation of genetic research. However, scientists have increasingly recognized that this pathway is not a simple assembly line. It is regulated by a vast network of over 170 different chemical modifications to RNA molecules. These marks act like molecular switches, dictating an RNA molecule's stability, its translation into protein, and its location within the cell.

Alida's new service focuses on three of the most abundant and functionally significant modifications. N6-methyladenosine (m6A) is the most prevalent internal modification on mRNA in mammals and plays a crucial role in everything from cell differentiation to immune response. Inosine is involved in editing RNA sequences, while pseudouridine, often called the “fifth nucleoside,” is known to stabilize RNA structure and modulate translation.

Of the three, pseudouridine has been the most elusive for researchers to study at scale. Its chemical structure is nearly identical to that of uridine, one of the four standard bases of RNA, making it incredibly difficult to distinguish with conventional sequencing methods. Previous approaches required large amounts of starting material, suffered from low sensitivity, and could not be easily multiplexed.

The EpiPlex Tri-Mod platform overcomes this long-standing hurdle with a proprietary, enzyme-driven chemistry. This technology specifically targets and converts pseudouridine into a distinct signal that can be read by next-generation sequencing (NGS) platforms with single-base resolution. This breakthrough is combined with a proximity barcoding strategy that simultaneously captures information about m6A and inosine from the same RNA fragment.

"EpiPlex's enzyme-based labeling of pseudouridine, combined with its proximity barcoding strategy, is designed to provide a level of sensitivity that is difficult to achieve with non-enrichment approaches," commented Wendy Gilbert, Ph.D., a Professor of Molecular Biophysics and Biochemistry at Yale University. "This opens the door to studying RNA modifications in lowly expressed transcripts that have historically been challenging to access."

A New Window into Disease Biology

The ability to profile these modifications is more than a technical achievement; it provides a direct, real-time snapshot of a cell's state. Unlike the relatively static genome, the epitranscriptome is highly dynamic, changing rapidly in response to environmental cues, metabolic stress, immune triggers, and the development of diseases like cancer. This layer of information has been a conspicuous blind spot for translational researchers aiming to connect molecular events to clinical outcomes.

With this new tool, scientists can now investigate how patterns of RNA modifications change during disease progression or in response to treatment. For example, aberrant m6A patterns have been linked to tumor growth and drug resistance in various cancers. The ability to simultaneously measure pseudouridine and inosine in the same samples provides a far more comprehensive picture of the regulatory landscape.

"What is especially exciting is the ability to look at multiple RNA modifications together," said Yi-Tao Yu, Ph.D., Professor of Biochemistry and Biophysics at the University of Rochester Medical Center. He noted that this capability finally allows researchers to test long-held suspicions about the interplay between different marks. "That gives researchers a real opportunity to ask whether one modification affects another, which has long been suspected but has been difficult to study directly. I think that is a major advantage of this method."

This multi-dimensional data is poised to have a significant impact on drug discovery and personalized medicine. By identifying unique epitranscriptomic signatures associated with specific diseases or patient responses, researchers can uncover novel biomarkers for early diagnosis, predict which patients are most likely to benefit from a particular therapy, and identify new targets for drug development.

Reshaping the RNA Analysis Market

Alida Biosciences' launch enters a rapidly growing market for advanced genomic and transcriptomic tools. The global epigenetics market was valued at over US$2 billion in 2024 and is projected to more than double by 2030, fueled by the demand for more sophisticated technologies in precision medicine and drug development. While several companies offer technologies for RNA analysis, Alida's claim to be the first with an integrated commercial NGS solution for the simultaneous detection of m6A, inosine, and pseudouridine positions it as a key innovator.

Other technologies, such as direct RNA sequencing offered by competitors like Oxford Nanopore, can also detect base modifications. However, Alida's approach differentiates itself by offering an end-to-end service, complete with proprietary chemistry optimized for sensitivity and its EpiScout™ analysis software. This integrated model is particularly valuable for researchers working with precious, RNA-limited clinical samples, such as tumor biopsies.

By providing both a full-service option and in-lab kits, the company is lowering the barrier to entry for a wide range of customers, from large biopharma companies to academic labs that may lack extensive bioinformatics infrastructure. This dual strategy could accelerate the adoption of epitranscriptomic analysis across the life sciences industry.

"RNA modifications are central to how cells respond to their environment," stated Gudrun Stengel, Ph.D., Chief Executive Officer of Alida Biosciences. "With EpiPlex Tri-Mod, we move beyond method development to enable large-scale studies that power AI-driven models and deepen understanding of biology in health and disease." The platform's ability to generate complex, multi-layered datasets is ideal for training machine learning algorithms to identify subtle patterns that are invisible to the human eye, potentially unlocking the next wave of biological discoveries and clinical breakthroughs.